Literature DB >> 16258161

Mass spectrometry-based loss of heterozygosity analysis of single-nucleotide polymorphism loci in paraffin embedded tumors using the MassEXTEND assay: single-nucleotide polymorphism loss of heterozygosity analysis of the protein tyrosine phosphatase receptor type J in familial colorectal cancer.

Marjo van Puijenbroek1, Jan Willem F Dierssen, Patrick Stanssens, Ronald van Eijk, Anne Marie Cleton-Jansen, Tom van Wezel, Hans Morreau.   

Abstract

As the number of identified single-nucleotide polymorphisms (SNPs) increases, high-throughput methods are required to characterize the informative loci in large patient series. We investigated the feasibility of MassEXTEND LOH analysis using Sequenom's MassArray RT software, a mass spectrometry method, as an alternative to determine loss of heterozygosity (LOH). For this purpose, we studied the c.827A>C SNP (1176A>C p.Gln276Pro) in protein tyrosine phosphatase receptor type-J (PTPRJ), which is frequently deleted in human cancers. In sporadic colorectal cancer (CRC), c.827A>C showed allele-specific LOH of the c.827A allele, which is important because LOH of PTPRJ may be an early event during sporadic CRC. To elucidate the impact of this low-penetrance gene on familial CRC, we studied c.827A>C in 222 familial CRC cases and 156 controls. In 6.2% of the A/C genotyped CRC samples, LOH of c.827A was observed with MassEXTEND LOH analysis and confirmed by conventional sequencing. Furthermore, a case with LOH of c.827A showed no LOH in 22 synchronously detected adenomas, including one with malignant transformation. The importance of the PTPRJ- c.827A>C SNP appears to be limited in familial CRC. We conclude that MassEXTEND LOH analysis (using Sequenom's MassARRAY RT software) is a sensitive, high-throughput, and cost-effective method to screen SNP loci for LOH in formalin-fixed paraffin-embedded tissue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258161      PMCID: PMC1867548          DOI: 10.1016/S1525-1578(10)60596-X

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  17 in total

Review 1.  Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry.

Authors:  T J Griffin; L M Smith
Journal:  Trends Biotechnol       Date:  2000-02       Impact factor: 19.536

Review 2.  MALDI-TOF-MS analysis of protein and DNA.

Authors:  T Bonk; A Humeny
Journal:  Neuroscientist       Date:  2001-02       Impact factor: 7.519

3.  Flow cytometric sorting of paraffin-embedded tumor tissues considerably improves molecular genetic analysis.

Authors:  Ekaterina S Jordanova; Willem E Corver; Marcel J Vonk; Math P G Leers; Sietske A Riemersma; Ed Schuuring; Philip M Kluin
Journal:  Am J Clin Pathol       Date:  2003-09       Impact factor: 2.493

4.  Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions.

Authors:  A M Cleton-Jansen; D F Callen; R Seshadri; S Goldup; B Mccallum; J Crawford; J A Powell; C Settasatian; H van Beerendonk; E W Moerland; V T Smit; W H Harris; R Millis; N V Morgan; D Barnes; C G Mathew; C J Cornelisse
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

5.  High-resolution multi-parameter DNA flow cytometry enables detection of tumour and stromal cell subpopulations in paraffin-embedded tissues.

Authors:  Willem E Corver; Natalja T Ter Haar; Enno J Dreef; Noel F C C Miranda; Frans A Prins; Ekaterina S Jordanova; Cees J Cornelisse; Gert Jan Fleuren
Journal:  J Pathol       Date:  2005-06       Impact factor: 7.996

6.  LOH of PTPRJ occurs early in colorectal cancer and is associated with chromosomal loss of 18q12-21.

Authors:  Claudia Ruivenkamp; Mario Hermsen; Cindy Postma; Anita Klous; Jan Baak; Gerrit Meijer; Peter Demant
Journal:  Oncogene       Date:  2003-05-29       Impact factor: 9.867

7.  Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer.

Authors:  Andrea E de Jong; Marjo van Puijenbroek; Yvonne Hendriks; Carli Tops; Juul Wijnen; Margreet G E M Ausems; Hanne Meijers-Heijboer; Anja Wagner; Theo A M van Os; Annette H J T Bröcker-Vriends; Hans F A Vasen; Hans Morreau
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

8.  Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers.

Authors:  Claudia A L Ruivenkamp; Tom van Wezel; Carlo Zanon; Alphons P M Stassen; Cestmir Vlcek; Tamás Csikós; Anita M Klous; Nikos Tripodis; Anastassis Perrakis; Lucie Boerrigter; Peter C Groot; Jan Lindeman; Wolter J Mooi; Gerrit A Meijjer; Gert Scholten; Hans Dauwerse; Vaclav Paces; Nico van Zandwijk; Gert Jan B van Ommen; Peter Demant
Journal:  Nat Genet       Date:  2002-06-24       Impact factor: 38.330

9.  Mutational analysis of the tyrosine phosphatome in colorectal cancers.

Authors:  Zhenghe Wang; Dong Shen; D Williams Parsons; Alberto Bardelli; Jason Sager; Steve Szabo; Janine Ptak; Natalie Silliman; Brock A Peters; Michiel S van der Heijden; Giovanni Parmigiani; Hai Yan; Tian-Li Wang; Greg Riggins; Steven M Powell; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-05-21       Impact factor: 47.728

10.  High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  K H Buetow; M Edmonson; R MacDonald; R Clifford; P Yip; J Kelley; D P Little; R Strausberg; H Koester; C R Cantor; A Braun
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

View more
  11 in total

1.  The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model.

Authors:  Daniel H Farkas; Nicholas E Miltgen; Jay Stoerker; Dirk van den Boom; W Edward Highsmith; Lesley Cagasan; Ron McCullough; Reinhold Mueller; Lin Tang; John Tynan; Courtney Tate; Allan Bombard
Journal:  J Mol Diagn       Date:  2010-07-08       Impact factor: 5.568

2.  Homozygously deleted gene DACH1 regulates tumor-initiating activity of glioma cells.

Authors:  Akira Watanabe; Hideki Ogiwara; Shogo Ehata; Akitake Mukasa; Shumpei Ishikawa; Daichi Maeda; Keisuke Ueki; Yasushi Ino; Tomoki Todo; Yasuhiro Yamada; Masashi Fukayama; Nobuhito Saito; Kohei Miyazono; Hiroyuki Aburatani
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-12       Impact factor: 11.205

3.  Comments on: "Meta-analysis of association between Arg326Gln (rs1503185) and Gln276Pro (rs1566734) polymorphisms of PTPRJ gene and cancer risk".

Authors:  Morteza Gholami; Mahsa M Amoli
Journal:  J Appl Genet       Date:  2019-07-12       Impact factor: 3.240

4.  The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family.

Authors:  Marjo van Puijenbroek; Maartje Nielsen; Tjitske H C M Reinards; Marjan M Weiss; Anja Wagner; Yvonne M C Hendriks; Hans F A Vasen; Carli M J Tops; Juul Wijnen; Tom van Wezel; Frederik J Hes; Hans Morreau
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

5.  Role of PTPRJ genotype in papillary thyroid carcinoma risk.

Authors:  Rodolfo Iuliano; Dario Palmieri; Huiling He; Angela Iervolino; Eleonora Borbone; Pierlorenzo Pallante; Alessandra Cianflone; Rebecca Nagy; Hansjuerg Alder; George A Calin; Francesco Trapasso; Carla Giordano; Carlo M Croce; Albert de la Chapelle; Alfredo Fusco
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

6.  A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.

Authors:  Debora Fumagalli; Patrick G Gavin; Yusuke Taniyama; Seung-Il Kim; Hyun-Joo Choi; Soonmyung Paik; Katherine L Pogue-Geile
Journal:  BMC Cancer       Date:  2010-03-16       Impact factor: 4.430

7.  Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer.

Authors:  Seema Sethi; Dejuan Kong; Sue Land; Gregory Dyson; Wael A Sakr; Fazlul H Sarkar
Journal:  Am J Transl Res       Date:  2013-03-28       Impact factor: 4.060

8.  Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers.

Authors:  Geraldine Perkins; Timothy A Yap; Lorna Pope; Amy M Cassidy; Juliet P Dukes; Ruth Riisnaes; Christophe Massard; Philippe A Cassier; Susana Miranda; Jeremy Clark; Katie A Denholm; Khin Thway; David Gonzalez De Castro; Gerhardt Attard; L Rhoda Molife; Stan B Kaye; Udai Banerji; Johann S de Bono
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

9.  Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique.

Authors:  Mark Kriegsmann; Norbert Arens; Volker Endris; Wilko Weichert; Jörg Kriegsmann
Journal:  Diagn Pathol       Date:  2015-07-30       Impact factor: 2.644

10.  The homeobox gene MEIS1 is methylated in BRAF (p.V600E) mutated colon tumors.

Authors:  Ashwin A Dihal; Arnoud Boot; Eddy H van Roon; Melanie Schrumpf; Arantza Fariña-Sarasqueta; Marta Fiocco; Eliane C M Zeestraten; Peter J K Kuppen; Hans Morreau; Tom van Wezel; Judith M Boer
Journal:  PLoS One       Date:  2013-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.